CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 602 enrolled
Drug / intervention
Telemedicineother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02933970
NCT02933970N/ACompleted
CompareCT.gov

Stepped-Wedge Randomized Control Trial to Compare Integrated, Co-located, Telemedicine-based HCV Management for Individuals on Opiate Agonist Treatment Versus Usual Care Treatment of HCV of Individuals on Opiate Agonist Treatment

Andrew Talal·interventional·Posted Oct 14, 2016·Updated Dec 20, 2024

In Brief

A clinical study evaluating Telemedicine for Hepatitis C. Completed, enrolled 602 participants across 1 site.

Detailed Summary

To compare the effectiveness of a patient-centered, opiate agonist treatment (OAT)-integrated telemedicine-based approach for management and delivery of hepatitis C virus (HCV) treatment to persons with substance use disorders (PWSUD) versus usual care, which we anticipate in most cases will be referral to an offsite location for HCV management. The effectiveness will be expressed through the primary patient centered and clinical outcome, achievement of viral eradication, defined as undetectable HCV RNA 12 weeks post-treatment cessation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 14, 2016
Enrollment StartFeb 28, 2017
Primary CompletionOct 1, 2020
Study CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago

Interventions

Telemedicineother

Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member